Iretig (Mirabegron)

Mirabegron selectively stimulates β3‑adrenergic receptors in the detrusor muscle of the bladder. This activation leads to muscle relaxation during the filling phase, which expands functional bladder capacity and lessens the frequency of unwanted bladder contractions that cause urgency and leakage.

The specific dose of Iretig is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and any concomitant medications. Dosage adjustments are made according to individual therapeutic needs and tolerability.

Safety data for mirabegron in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare professional.

To request Iretig, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Antimuscarinic drugs reduce bladder contractions by blocking muscarinic receptors, whereas Iretig (mirabegron) increases bladder capacity through β3‑adrenergic stimulation. Mirabegron often has a lower incidence of dry mouth and constipation, common side effects of antimuscarinics, but may raise blood pressure in some patients.

Iretig should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, controlled environment helps maintain its stability and potency throughout its shelf life.

Iretig is taken orally, usually once daily, with or without food, as directed by the prescribing physician. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include acute urinary retention, severe hypertension, and rare allergic reactions such as anaphylaxis. Patients should be monitored for signs of these events, and any sudden changes in urinary function or blood pressure should prompt immediate medical evaluation.

Iretig is contraindicated in patients with uncontrolled hypertension, severe urinary retention, or known hypersensitivity to mirabegron or any excipients. Caution is also advised for individuals taking strong CYP2D6 inhibitors or those with significant renal impairment.